Compare Gitlab Inc (GTLB) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gitlab Inc vs Philip Morris International Inc. — how do they compare? Gitlab Inc trades at $53.9 (market cap $8.92B), while Philip Morris International Inc. trades at $199.94 (market cap $312.50B). The key difference: Philip Morris International Inc. is far larger — about 35× Gitlab Inc's market cap, and Philip Morris International Inc. pays a 3.19% dividend while Gitlab Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gitlab Inc for 62 Days and Philip Morris International Inc. for 85 Days on average.
| GTLB | PM | |
|---|---|---|
Market Cap | $8.92B | $312.50B |
Volume | 4,716,893 | 5,517,172 |
Sector | Technology | Consumer Staples |
52-Week High | $53.56 | $200.50 |
52-Week Low | $19.42 | $144.33 |
Typical Hold Time | 62 Days | 85 Days |
Enterprise Value | $7.66B | $355.62B |
Dividend Yield | — | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GitLab (GTLB) trades at $51.99, up 0.7% on the day and near its 52-week high, supported by a bullish technical outlook and strong Q2 2026 earnings beats. Revenue growth accelerated to 21.3% year-over-year, with the company raising full-year guidance amid robust AI-driven demand for its DevSecOps platform. However, the stock trades at a high P/E ratio of 521.22, reflecting premium valuation despite negative net income margins.
The investment case hinges on GitLab's execution in monetizing AI and enterprise expansion, but risks include sustained profitability challenges and competitive pressure. Analysts are mixed with a Hold consensus, yet recent news highlights sales momentum and institutional interest, suggesting potential upside if growth targets are met.
Philip Morris International (PM) trades at $192.69, up 1.2% today, with a bullish technical signal and strong analyst support. Recent Q2 2026 EPS beat expectations at $2.20 vs. $2.05, and revenue growth accelerated to $40.65B in 2025. The company's smoke-free products now drive 42% of revenue, with ZYN and IQOS expansions fueling optimism. Cash flow remains robust, with 2026 operating cash flow projected at $14.3B, supporting dividend growth.
Outlook is positive given earnings momentum and smoke-free transition, but high debt ($42.17B long-term) and regulatory risks persist. The consensus price target of $212.17 implies ~10% upside, though valuation multiples are elevated versus peers. Key risks include FX volatility and slower adoption of next-gen products.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
